PMID- 23684449
OWN - NLM
STAT- MEDLINE
DCOM- 20150430
LR  - 20181202
IS  - 1872-8227 (Electronic)
IS  - 0168-8227 (Linking)
VI  - 101
IP  - 1
DP  - 2013 Jul
TI  - Effect of indomethacin on cerebrovascular reactivity in patients with type 2 
      diabetes mellitus.
PG  - 81-7
LID - S0168-8227(13)00160-5 [pii]
LID - 10.1016/j.diabres.2013.04.004 [doi]
AB  - AIM: Impaired cerebral vasoreactivity to endothelium-dependent stimuli were 
      described in type 2 diabetes mellitus (T2DM), but the mechanisms underlying that 
      impairment are still unclear. The aim of this study was to investigate the role 
      of cyclooxygenases' metabolites in response to acute hypercapnic stimulus in 
      cerebral vessels, in patients with T2DM. METHODS: Vascular responses in the 
      breath-holding test (BHT) were assessed in the absence/presence of a 
      non-selective, reversible-inhibitor of cyclooxygenases, indomethacin (INDO), by 
      functional transcranial Doppler sonography of the middle cerebral artery (N of 
      patients=50; 33 men and 17 women). The functional hemodynamic parameter mean flow 
      velocity (MFV) was assessed at rest, before and 90min after 100mg of INDO, and 
      during the BHT. Breath holding index (BHI) [(MFV at the end of BHT minus MFV at 
      rest)/MFV at rest)x100/s of breath-holding] was calculated after BHT performed 
      before and 90min after INDO. RESULTS: MFV at rest significantly decreased after 
      INDO administration compared with a control condition before INDO (at rest before 
      INDO from 49.36+/-15.09 to 36.72+/-8.45 after INDO, p<0.001) However, overall 
      cerebral vessel vasoreactivity to hypercapnia, evaluated with BHI, was 
      significantly improved after INDO administration compared with the BHI before 
      INDO administration (from 0.68+/-0.4 to 1.27+/-0.42, p<0.001). CONCLUSIONS: The 
      improvement in cerebral vasoreactivity in response to BHT after INDO 
      administration suggests that the production of a vasoconstrictor metabolite of 
      cyclooxygenase in diabetic patients was reduced by indomethacin consumption.
CI  - Copyright (c) 2013 Elsevier Ireland Ltd. All rights reserved.
FAU - Vuletic, Vladimira
AU  - Vuletic V
AD  - Department of Neurology, Dubrava University Hospital, Zagreb, Croatia. Electronic 
      address: vvuletic@kbd.hr.
FAU - Drenjancevic, Ines
AU  - Drenjancevic I
AD  - Department of Physiology and Immunology, Faculty of Medicine Osijek, University 
      Josip, Juraj Strossmayer, Osijek, Croatia.
FAU - Rahelic, Dario
AU  - Rahelic D
AD  - Department of Endocrinology, Diabetes and Metabolic Disorders, Dubrava University 
      Hospital, Zagreb, Croatia.
FAU - Demarin, Vida
AU  - Demarin V
AD  - Medical Director, Medical Centre "Aviva", Zagreb, Croatia.
LA  - eng
PT  - Journal Article
PT  - Randomized Controlled Trial
DEP - 20130515
PL  - Ireland
TA  - Diabetes Res Clin Pract
JT  - Diabetes research and clinical practice
JID - 8508335
RN  - 0 (Cardiovascular Agents)
RN  - XXE1CET956 (Indomethacin)
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Aged
MH  - Brain/*drug effects
MH  - Cardiovascular Agents/*pharmacology
MH  - Cerebrovascular Circulation/*drug effects
MH  - Diabetes Mellitus, Type 2/*drug therapy/physiopathology
MH  - Female
MH  - Follow-Up Studies
MH  - Hemodynamics
MH  - Humans
MH  - *Hypercapnia
MH  - Indomethacin/*pharmacology
MH  - Male
MH  - Middle Aged
MH  - Middle Cerebral Artery/*drug effects
MH  - Prognosis
MH  - Prospective Studies
MH  - Ultrasonography, Doppler, Transcranial
MH  - Young Adult
EDAT- 2013/05/21 06:00
MHDA- 2015/05/01 06:00
CRDT- 2013/05/21 06:00
PHST- 2013/01/29 00:00 [received]
PHST- 2013/03/21 00:00 [revised]
PHST- 2013/04/22 00:00 [accepted]
PHST- 2013/05/21 06:00 [entrez]
PHST- 2013/05/21 06:00 [pubmed]
PHST- 2015/05/01 06:00 [medline]
AID - S0168-8227(13)00160-5 [pii]
AID - 10.1016/j.diabres.2013.04.004 [doi]
PST - ppublish
SO  - Diabetes Res Clin Pract. 2013 Jul;101(1):81-7. doi: 
      10.1016/j.diabres.2013.04.004. Epub 2013 May 15.